The Incorrect Statement is D: Relapse After Treatment is Rare (Less Than 1%)
Statement D is definitively incorrect—relapse after treatment in minimal change disease is actually very common, occurring in more than 50% of patients, not less than 1%. 1
Analysis of Each Statement
A) Most Common Cause of Proteinuric Renal Disease in Children - CORRECT
MCD accounts for more than 75% of all pediatric nephrotic syndrome cases and 90% of cases in children under 5 years of age 1. This makes it unequivocally the most common cause of proteinuric renal disease in the pediatric population.
B) Excellent Response to Corticosteroids - CORRECT
Approximately 95% of children with MCD achieve complete remission with corticosteroid therapy 1. Adults show a somewhat lower but still excellent response rate of 50-80% depending on treatment duration 1. The treatment algorithm clearly demonstrates corticosteroids as first-line therapy with high efficacy 1.
C) Characteristic Biopsy Finding is Podocyte Effacement - CORRECT
Podocyte foot process effacement on electron microscopy is the pathologic hallmark of MCD 2. Light microscopy shows no visible glomerular alterations, but electron microscopy reveals extensive podocyte foot process effacement as the defining diagnostic feature 2, 3.
D) Relapse After Treatment is Rare (Less Than 1%) - INCORRECT
This statement is completely false. More than half of all patients who initially respond to steroids experience relapses 1. The evidence is clear:
- Children: Relapse occurs in approximately 71% of pediatric patients 4
- Adults: Relapse rates reach up to 85% in adult patients 4
- The guideline explicitly states that "more than half of all patients who are initially steroid responsive go on to experience relapses" 1
- Those who relapse frequently (≥2 episodes within 6 months) have greater risk of becoming steroid-dependent 1
- Relapses occur most commonly in the first 6-12 months after achieving remission 4
The treatment algorithms specifically include pathways for managing "frequent relapses" and "steroid dependency," which would be unnecessary if relapse rates were truly less than 1% 1.
E) Progression to Chronic Kidney Disease is Rare - CORRECT
The risk of end-stage renal disease (ESRD) in MCD is extremely low 1. Long-term outcome data shows:
- Fewer than 5% of patients progress to ESRD 4
- Patient survival is 83-98% at 15 years 4
- Forms of MCD that respond to steroids "usually do not lead to chronic renal damage" 2
- The only exceptions are severe acute tubular necrosis in elderly patients or those with pre-existing severe hypertension 1
Clinical Implications
The high relapse rate necessitates:
- Monthly dipstick surveillance to detect relapses requiring short courses of steroids 1
- Consideration of steroid-sparing agents (cyclosporin, cyclophosphamide, rituximab) for frequent relapsers or steroid-dependent patients 1
- Long-term follow-up even after achieving initial remission
The excellent prognosis regarding kidney function (statement E) provides reassurance, but the high relapse rate (contradicting statement D) means patients require ongoing monitoring and often multiple treatment courses throughout their disease course.